139 related articles for article (PubMed ID: 37259544)
1. Treatment preferences among patients with mild-to-moderate atopic dermatitis.
Myers K; Silverberg JI; Parasuraman S; Pierce A; Eichenfield LF; Poulos C
J Dermatolog Treat; 2023 Dec; 34(1):2215356. PubMed ID: 37259544
[No Abstract] [Full Text] [Related]
2. Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment.
Boeri M; Sutphin J; Hauber B; Cappelleri JC; Romero W; Di Bonaventura M
J Dermatolog Treat; 2022 May; 33(3):1449-1458. PubMed ID: 33023361
[TBL] [Abstract][Full Text] [Related]
3. Adult, adolescent, and caregiver preferences for attributes of topical treatments for mild-to-moderate atopic dermatitis: a discrete-choice experiment.
Feldman SR; Thyssen JP; Boeri M; Gerber R; Neary MP; Cha A; Hauber B; Cappelleri JC; Xenakis J; Leach C; Zeichner J
J Dermatolog Treat; 2024 Dec; 35(1):2304020. PubMed ID: 38221777
[No Abstract] [Full Text] [Related]
4. Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment.
Feldman SR; Guerin A; Gauthier-Loiselle M; Claxton AJ; Hazra NC; Meng Y; Gallant K; Balu S
J Dermatolog Treat; 2024 Dec; 35(1):2345739. PubMed ID: 38705585
[No Abstract] [Full Text] [Related]
5. Patient preferences for atopic dermatitis treatments: a discrete choice experiment.
Kwatra SG; Lio P; Weidinger S; Calimlim B; Ladizinski B; Vigna N; Botha W; Mansfield C
J Dermatolog Treat; 2023 Dec; 34(1):2222201. PubMed ID: 37349865
[TBL] [Abstract][Full Text] [Related]
6. Quantifying Physician Preferences for Systemic Atopic Dermatitis Treatments Using a Discrete-Choice Experiment.
Carrascosa Carrillo JM; Baselga Torres E; Gilaberte Calzada Y; Jurgens Martínez YN; Roustan Gullón G; Yanguas Bayona JI; Gómez Castro S; Ferrario MG; Rebollo Laserna FJ
Dermatol Ther (Heidelb); 2022 May; 12(5):1197-1210. PubMed ID: 35445962
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2023 Jan; 24(1):143-151. PubMed ID: 36538235
[TBL] [Abstract][Full Text] [Related]
8. Patient and physician preferences for atopic dermatitis injection treatments in Japan.
Okubo Y; Ho KA; Fifer S; Fujita H; Oki Y; Taguchi Y
J Dermatolog Treat; 2020 Dec; 31(8):821-830. PubMed ID: 31250681
[No Abstract] [Full Text] [Related]
9. Patient Preferences in the Treatment of Moderate-to-severe Atopic Dermatitis.
Ameen M; Alhusayen R; Brandi H; Bøgelund M; Jensen HH; Reitzel SB; Thyssen JP
Acta Derm Venereol; 2024 Feb; 104():adv24339. PubMed ID: 38380974
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
11. Patient preferences for atopic dermatitis medications in the UK, France and Spain: a discrete choice experiment.
Thomas C; Raibouaa A; Wollenberg A; Capron JP; Krucien N; Karn H; Tervonen T
BMJ Open; 2022 Aug; 12(8):e058799. PubMed ID: 35918108
[TBL] [Abstract][Full Text] [Related]
12. A starch, glycyrretinic, zinc oxide and bisabolol based cream in the treatment of chronic mild-to-moderate atopic dermatitis in children: a three-center, assessor blinded trial.
Licari A; Ruffinazzi G; DE Filippo M; Castagnoli R; Marseglia A; Agostinis F; Puviani M; Milani M; Marseglia GL
Minerva Pediatr; 2017 Dec; 69(6):470-475. PubMed ID: 29181960
[TBL] [Abstract][Full Text] [Related]
13. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
14. Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States.
Feldman SR; Holmen Moeller A; Erntoft Idemyr ST; González JM
J Health Econ Outcomes Res; 2017; 4(2):141-157. PubMed ID: 37661952
[No Abstract] [Full Text] [Related]
15. A Novel Multi-Action Emollient Plus Cream Improves Skin Barrier Function in Patients with Atopic Dermatitis: In vitro and Clinical Evidence.
Quadri M; Lotti R; Bonzano L; Ciardo S; Guanti MB; Pellacani G; Pincelli C; Marconi A
Skin Pharmacol Physiol; 2021; 34(1):8-18. PubMed ID: 33601378
[TBL] [Abstract][Full Text] [Related]
16. Novel topical agent containing superoxide dismutase 100 000 IU and 4% of plant extracts as a mono-therapy for atopic dermatitis.
Sgouros D; Katoulis A; Rigopoulos D
J Cosmet Dermatol; 2018 Dec; 17(6):1069-1072. PubMed ID: 29134748
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Atopic Dermatitis in the United States: Analysis of Data from the National Ambulatory Medical Care Survey.
McGregor SP; Farhangian ME; Huang KE; Feldman SR
J Drugs Dermatol; 2017 Mar; 16(3):250-255. PubMed ID: 28301621
[TBL] [Abstract][Full Text] [Related]
18. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial.
Miller DW; Koch SB; Yentzer BA; Clark AR; O'Neill JR; Fountain J; Weber TM; Fleischer AB
J Drugs Dermatol; 2011 May; 10(5):531-7. PubMed ID: 21533301
[TBL] [Abstract][Full Text] [Related]
19. Adolescents' Perspectives on Atopic Dermatitis Treatment-Experiences, Preferences, and Beliefs.
Kosse RC; Bouvy ML; Daanen M; de Vries TW; Koster ES
JAMA Dermatol; 2018 Jul; 154(7):824-827. PubMed ID: 29847623
[TBL] [Abstract][Full Text] [Related]
20. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
